ERBB2 and breast cancer: Further, we compared the prediction scores of the 25-gene signature classifier between pCR and RD samples or different subtypes, and the results showed that it could distinguish the two groups of samples well, both in the training and test sets (Figure 2C) and between HER2-positive (HR-negative), HER2-positive (HR-positive), Luminal (A/B), and TNBC subtypes of breast cancer (Figure 2D).